Shaldam Moataz, Tawfik Haytham, Elmansi Heba, Belal Fathalla, Yamaguchi Koki, Sugiura Masaharu, Magdy Galal
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
J Biomol Struct Dyn. 2023 Oct-Nov;41(18):8876-8890. doi: 10.1080/07391102.2022.2138551. Epub 2022 Oct 30.
In the present study, a drug-like molecular hybrid structure between chalcone and sulfonamide moieties was synthesized and characterized. The structural peculiarities of the synthesized hybrid were further verified by means of single crystal X-ray crystallography. Furthermore, its biological activity as an anticancer agent was evaluated. The synthesized model of chalcone-sulfonamide hybrid was found to have potent anticancer properties against the studied cancer cell lines. Hence, the binding interaction of hybrid with Calf thymus DNA (CT-DNA) was studied at a simulated physiological pH to confirm its anticancer activity for the first time. This was investigated by applying different spectroscopic techniques, ionic strength measurements, viscosity measurements, thermodynamics, molecular dynamic simulation and molecular docking studies. The obtained results showed a clear binding interaction between hybrid and CT-DNA with a moderate affinity a minor groove binding mechanism. The binding constant () at 298 K calculated from the Benesi-Hildebrand equation was found to be 3.49 × 10 M. The entropy and enthalpy changes ( and ) were 204.65 J mol K and 35.08 KJ mol, respectively, indicating that hydrophobic interactions constituted the major binding forces. The results obtained from molecular docking and dynamic simulation studies confirmed the minor groove binding interaction and the stability of the formed complex. This study can contribute to further understanding of the molecular mechanism of hybrid as a potential antitumor agent and can also guide future clinical and pharmacological studies for rational drug design with enhanced or more selective activity and greater efficacy.[Figure: see text]Communicated by Ramaswamy H. Sarma.
在本研究中,合成并表征了查尔酮与磺酰胺部分之间的类药物分子杂化结构。通过单晶X射线晶体学进一步验证了合成杂化物的结构特性。此外,评估了其作为抗癌剂的生物活性。发现合成的查尔酮-磺酰胺杂化物模型对所研究的癌细胞系具有有效的抗癌特性。因此,首次在模拟生理pH条件下研究了杂化物与小牛胸腺DNA(CT-DNA)的结合相互作用,以确认其抗癌活性。通过应用不同的光谱技术、离子强度测量、粘度测量、热力学、分子动力学模拟和分子对接研究对此进行了研究。获得的结果表明杂化物与CT-DNA之间存在明显的结合相互作用,具有中等亲和力和小沟结合机制。根据贝内西-希尔德布兰德方程计算,298K时的结合常数()为3.49×10 M。熵变和焓变(和)分别为204.65 J mol K和35.08 KJ mol,表明疏水相互作用构成了主要的结合力。分子对接和动态模拟研究获得的结果证实了小沟结合相互作用以及形成的复合物的稳定性。本研究有助于进一步了解杂化物作为潜在抗肿瘤剂的分子机制,也可为未来的临床和药理学研究提供指导,以进行具有增强或更具选择性活性及更高疗效的合理药物设计。[图:见正文]由拉马斯瓦米·H·萨尔马传达。